Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03473756
Recruitment Status : Active, not recruiting
First Posted : March 22, 2018
Last Update Posted : November 15, 2021
Sponsor:
Information provided by (Responsible Party):
Bayer

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : July 16, 2021
Estimated Study Completion Date : December 23, 2022